Search and Destroy

Radionuclides that target and kill advanced prostate cancer cells show great promise.
It is estimated that 34,500 men in the United States die from prostate cancer each year, making it the second leading cause of cancer death among males in America. Some prostate cancers are slow growing, but others are advanced (metastatic). Approximately one-half of men with prostate cancer eventually develop metastatic disease. One type of metastatic disease, metastatic castration-resistant prostate cancer (mCRPC), which is able to grow and spread despite hormone therapy, is particularly lethal. It has a median life expectancy of five years. Read more…